Shiratronics Inc. raised $66 million in an oversubscribed series B financing round to support completion of its recently ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money ...

With confidence dropping in doing business with China-affiliated life sciences companies due to the Biosecure Act, one of the companies explicitly named in the U.S. legislation is fighting back.

David Baker, Demis Hassabis and John Jumper share the 2024 Nobel Prize in Chemistry for their contributions to the science of protein structure. David Baker was awarded half the prize “for ...

Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) are involved in the regulation of transcription elongation, DNA damage response and genomic stability balance. A few inhibitors of CDK12- and CDK13 ...

GE Healthcare Technologies Inc. is participating in the €25.3 million (US$27.8 million) Thera4care project that aims to ...

It’s hard to know where to start in describing the biopharma applications of the 2024 Nobel Prize in Physics. It was awarded ...

Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 ...

Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...

David Baker, director of the Institute for Protein Design at the University of Washington School of Medicine, is a pioneer in protein design. His contributions have been recognized with countless ...

A digital cognitive assessment developed by Braincheck Inc., Braincheck Assess, proved comparable to the gold-standard ...

The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe ...